Status In progress
Process CDF Review
ID number 1572

Provisional Schedule

Final appraisal document: 2 03 June 2021 - 17 June 2021
Expected publication 07 July 2021

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Bristol-Myers Squibb (nivolumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Lilly UK (pemetrexed, gemcitabine) (confidentiality agreement signed, participating)
  Pfizer (cisplatin, crizotinib) (confidentiality agreement signed, participating)
  Roche Products (erlotinib) (confidentiality agreement signed, participating)
  Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Actavis UK (docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Boehringer Ingelheim (nintedanib, afatinib) (confidentiality agreement not signed, not participating)
  Hospira UK (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac UK (docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals (certitinib) (confidentiality agreement not signed, not participating)
  Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel) (confidentiality agreement not signed, not participating)
  Sun Pharmaceuticals (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Teva UK (docetaxel) (confidentiality agreement not signed, not participating)
  Wockhardt UK (vinorelbine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
31 March 2021 After further consideration, rather than issuing an updated scope and inviting evidence submissions related to this, we have agreed that the best way forward is to seek input from consultees and commentators on the process of the review. Consultees and commentators have been invited to provide comments by 30th April. A further update will follow once the responses have been considered.
27 November 2020 Appeal
27 November 2020 The appeal hearing in relation to this appraisal which was scheduled for Tuesday 1 December 2020 has been cancelled. This is because NICE has formally withdrawn the Final Appraisal Document which was issued on 17 September 2020. NICE now intends to issue an updated scope and invite registered stakeholders to submit any further information or evidence related to the updated scope which may not have been included in their original submission. These submissions will then be presented to the Appraisal Committee for consideration.
17 September 2020 - 01 October 2020 Final appraisal document
10 September 2020 In progress. Having been paused due to COVID-19, this appraisal has been scheduled back into the NICE work programme.
05 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
07 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
18 March 2020 Committee meeting: 1
06 December 2019 Appraisal in progress.
03 September 2019 This appraisal topic is paused to allow the company to provide updated submission documentation. The appraisal will be rescheduled into the work programme and the updated appraisal timelines will be communicated, once known.
19 July 2019 Invitation to participate
11 July 2019 In progress. Start date of invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance